ArticleProstate cancer and prostatic diseases2025
Undetected Cribriform and Intraductal Prostate Cancer at biopsy is associated with adverse outcomes.
Article in Prostate cancer and prostatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Cribriform and intraductal carcinoma in prostate cancer - implications for risk stratification and therapeutic decision-making.Nature reviews. Urology · 2026Review
- Reply to Dr. Zhang's Letter to the Editor re: R.M. Bernardino, L.B. Yin, K. Lajkosz, et al. Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective Trial. Eur Urol Open Sci 2025;82:52-8.European urology open science · 2026Article
- Prognostic value of cribriform pattern and intraductal carcinoma of the prostate after radical prostatectomy: A systematic review and meta-analysis using contemporary consensus recommendations.Prostate cancer and prostatic diseases · 2026Review
- ISUP Grade Group Migration Between Prostate Biopsy and Radical Prostatectomy: A Systematic Review of Emerging Predictors.Biomedicines · 2026Review
- Identification of factors associated with intraductal carcinoma of the prostate.Diagnostic pathology · 2026Article
- Article
- Atypical intraductal proliferation in prostate biopsy - a diagnostic grey zone with clinical implications.Nature reviews. Urology · 2026Review
- Re: Rui M. Bernardino, Leyi B. Yin, Katherine Lajkosz, et al. Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective Trial. Eur Urol Open Sci 2025;82:52-8.European urology open science · 2026Article
- Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective Trial.European urology open science · 2025Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIntraductal carcinoma (IDC) and cribriform pattern (Crib) of prostate cancer are increasingly recognized as independent prognosticators of poor outcome, both in prostate biopsies and radical prostatectomy (RP) specimens.
objectiveThe aim of our project is to assess the impact of false negative biopsies for these two characteristics on oncological outcomes. MATERIAL AND
methodsPatients who underwent RP between January 2015 and December 2022 were included in the study. Predictors of Biochemical Failure were examined using a multivariate Cox proportional hazards model. RESULTS AND LIMITATION: Among the 836 patients who underwent RP, 233 (27.9%) had Crib, and 125 (15.0%) had IDC on prostate biopsy, with 71 (8.5%) patients having both IDC and Crib. Concerning IDC/Crib status at biopsy, 217 (26%) patients had a false-negative biopsy, 332 (39.7%) had a true-negative biopsy, 256 (30.6%) showed a true-positive biopsy, and 24 (3.7%) exhibited a false-positive biopsy, with respect to either pattern. When comparing false-negative, false-positive, true-negative and true-positive biopsies for IDC/Crib, we found that patients with a false-negative biopsy for IDC/Crib versus those with a true-negative biopsy for IDC/Crib disclosed a rate of advanced pathological stage (≥pT3) which was twice that of patients with a true-negative biopsy for IDC/Crib: 56.8% versus 28.1%, respectively (p < 0.001). On multivariate Cox analysis, log PSA before RP (hazard ratio [HR] 2.07, 95% CI 1.53-2.82; p < 0.001), a higher percentage of positive cores at biopsy ( ≥ 33%) (HR 1.68, 95% CI 1.07-2.63; p = 0.024), and false negative biopsy for IDC/Crib (HR 2.14, 95% CI 1.41-3.25; p < 0.001), were each significantly associated with an increased risk of BCR.
conclusionsA false-negative biopsy for IDC/Crib is independently associated with higher risk of BCR and advanced pathological stage compared to a true negative biopsy.
Indexed as
Identifiers
39433886What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.